The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis Clinical Trial

Official title:

The INVIGORATE 2 Trial: A Single-center, Randomized, Double-masked, Crossover Design, Vehicle-controlled, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Reproxalap Ophthalmic Solution (0.25%) Compared to Vehicle in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05234554
• Other study ID #: ADX-102-AC-026
• Status: Completed
• Phase: Phase 3
• Start date: January 21, 2022
• Est. completion date: April 22, 2023

Study information

• Verified date: April 2024
• Source: Aldeyra Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The INVIGORATE 2 Trial: A single-center, randomized, double-masked, crossover design, vehicle-controlled, Phase 3 clinical trial to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared to vehicle in subjects with seasonal allergic conjunctivitis using the environmental exposure chamber (EEC).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 131
• Est. completion date: April 22, 2023
• Est. primary completion date: April 22, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Be at least 18 years of age at the time of screening of either sex or any race;

• Provide written informed consent;

• Be willing and able to follow instructions, and can attend all required clinical trial visits.

• Have at least a two-year history of moderate-to-severe ragweed-induced allergic conjunctivitis based on investigator's judgement;

• Have a positive skin prick test to ragweed pollen within the past year of the Medical Screening Visit (Visit 1).

Exclusion Criteria:

• Have a history of blepharitis, dry eye syndrome, herpes simplex keratitis, or herpes zoster keratitis;

• Have systemic signs of infection (e.g., fever, current treatment with antibiotics).

• Have a systemic disease or uncontrolled medical condition, which, in the opinion of the investigator, could interfere with clinical trial measurements or subject compliance. Such diseases or conditions would include, but are not limited to, cancer, alcoholism, drug dependency or abuse, or psychiatric disease;

• Be a WOCBP who is pregnant, nursing, or not using an effective means of contraception;

• Have any known contraindication or hypersensitivities to any components of the Investigational Product (IP) drug formulation.

Related Conditions & MeSH terms

• Allergic Conjunctivitis
• Conjunctivitis
• Conjunctivitis, Allergic

Intervention

Drug:
• Reproxalap Ophthalmic Solution (0.25%)
Reproxalap Ophthalmic Solution (0.25%) dosed twice.
• Vehicle Ophthalmic Solution
Vehicle Ophthalmic Solution dosed twice.

Locations

Country	Name	City	State
Canada	Cliantha Research	Mississauga	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Aldeyra Therapeutics, Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ocular itching evaluated by the Subject.	The method of assessment for the primary outcome is a 9-point ocular itch scale (0 none - 4 severe).	During EEC allergen exposure.
Secondary	Conjunctival redness evaluated by the Subject.	The method of assessment for the key secondary outcome is a 9-point ocular redness scale (0 none - 4 extremely severe).	During EEC allergen exposure.